{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:28:39Z","timestamp":1785403719540,"version":"3.56.0"},"reference-count":26,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA039192"],"award-info":[{"award-number":["R01DA039192"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"award":["R01DA039192"],"award-info":[{"award-number":["R01DA039192"]}],"id":[{"id":"https:\/\/ror.org\/00fq5cm18","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Background: Co-prescribing opioids and gabapentinoids (GABA, gabapentin and pregabalin) is associated with increased risk of falls, fractures, opioid overdose and deaths. The Centers for Disease Control and Prevention (CDC) in 2016 and the Food and Drug Administration (FDA) in 2019 recommended caution in such co-prescribing. A key step in updating policy and revising prescribing guidelines aimed at reducing opioid and GABA co-use and its associated consequences is a thorough understanding of the prescriber and the patient factors associated with co-use. We thus examined national trends and patterns in opioid and GABA co-prescribing among Medicare beneficiaries from 2017 to 2022. Methods: We conducted a retrospective study of Medicare beneficiaries with \u226590 consecutive days of opioid use from 2017 to 2022. The study outcome was GABA use during the 90-day opioid use episode. A multivariable logistic regression model was constructed to examine the patient, prescriber and prescription factors associated with receiving a GABA prescription. Results: Our sample comprised 8035 opioid-only and 2818 opioid and GABA users. Non-cancer (e.g., back and neuropathic) pain was a more common diagnosis in the opioid and GABA cohorts than in the opioid-only cohorts. The opioid-GABA co-prescribing rate did not substantially change (2017: 24.5%, 2019: 28.2% and 2022: 25%). Co-prescribing rates were higher in non-white patients, those on Medicaid and Medicare, and those whose initial Medicare entitlement was not based on age. Tramadol and hydrocodone were the most prescribed opioids. Approximately 33% of opioid and GABA users started with an initial daily GABA dose of \u22651200 mg. In the 12-month lookback period, patients on opioids and GABA had nearly 17 clinic visits to approximately 8 different providers. Factors associated with co-prescribing were seeing pain physicians (odds ratio = 1.29, 95% confidence interval-[CI] = 1.11\u20131.50), having more healthcare encounters (6\u201311 visits, odds ratio-[OR] = 1.19, 95% CI = 1.02\u20131.39; 12\u201319, OR = 1.20, 95% CI = 1.00\u20131.43; 20+, OR = 1.27, 95% CI = 1.03\u20131.57) and seeing &gt;10 providers (OR = 1.40, 95% CI = 1.12\u20131.73). Conclusions: One in four Medicare beneficiaries with long-term opioid use received opioid and GABA prescriptions. Our findings of association in co-prescribing with multiple visits to different clinics\/prescribers can inform the development of public health policy and practice guidelines (e.g., prescription-drug monitoring program checks within electronic medical records, EMR alerts with opioid and GABA co-prescribing) to potentially reduce opioid and GABA prescriptions and associated adverse outcomes.<\/jats:p>","DOI":"10.3390\/medsci14030345","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:37:55Z","timestamp":1782391075000},"page":"345","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in Co-Prescribing Opioids and Gabapentinoids Among Medicare Beneficiaries, 2017 to 2022"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7460-7281","authenticated-orcid":false,"given":"Mukaila","family":"Raji","sequence":"first","affiliation":[{"name":"Division of Geriatrics, Department of Internal Medicine, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA"},{"name":"John Sealy School of Medicine, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashnika","family":"Sujit","sequence":"additional","affiliation":[{"name":"John Sealy School of Medicine, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-1766","authenticated-orcid":false,"given":"Jordan","family":"Westra","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public and Population Health, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9741-6768","authenticated-orcid":false,"given":"Shilpa","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"John Sealy School of Medicine, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1927-0927","authenticated-orcid":false,"given":"Yong-Fang","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics & Data Science, School of Public and Population Health, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"ref_1","unstructured":"American Medical Association (2025, May 28). Overdose Epidemic Report 2024: Physicians\u2019 Actions to Help End the Nation\u2019s Drug-Related Overdose and Death Epidemic\u2014And What Still Needs to be Done. Publication 24-117708. Available online: https:\/\/www.ama-assn.org\/system\/files\/ama-overdose-epidemic-report.pdf."},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (2025, May 28). 2022 CDC Clinical Practice Guideline at a Glance. 7 May 2024, Available online: https:\/\/www.cdc.gov\/overdose-prevention\/hcp\/clinical-guidance\/index.html."},{"key":"ref_3","first-page":"1","article-title":"CDC Guideline for Prescribing Opioids for Chronic Pain\u2014United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.burns.2021.12.006","article-title":"Prescribing of gabapentinoids with or without opioids after burn injury in the US, 2012-2018","volume":"48","author":"Polychronopoulou","year":"2022","journal-title":"Burns"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.amepre.2021.08.024","article-title":"Concurrent use of prescription opioids and gabapentinoids in older adults","volume":"62","author":"Chen","year":"2022","journal-title":"Am. J. Prev. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2318626","DOI":"10.1001\/jamanetworkopen.2023.18626","article-title":"Trends in the use of gabapentinoids and opioids in the postoperative period among older adults","volume":"6","author":"Bongiovanni","year":"2023","journal-title":"JAMA Netw. Open."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain\u2014Is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gomes, T., Juurlink, D.N., Antoniou, T., Mamdani, M.M., Paterson, J.M., and van den Brink, W. (2017). Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med., 14.","DOI":"10.1371\/journal.pmed.1002396"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40264-017-0595-1","article-title":"All-cause and drug-related medical events associated with overuse of gabapentin and\/or opioid medications: A retrospective cohort analysis of a commercially insured US population","volume":"41","author":"Peckham","year":"2018","journal-title":"Drug Saf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/add.15189","article-title":"Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: A retrospective cohort study","volume":"116","author":"Zhou","year":"2021","journal-title":"Addiction"},{"key":"ref_11","first-page":"100302","article-title":"Adverse outcomes associated with concurrent gabapentin, opioid, and benzodiazepine utilization: A nested case-control study","volume":"13","author":"Olopoenia","year":"2022","journal-title":"Lancet Reg. Health\u2013Am."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.15585\/mmwr.mm7119a3","article-title":"Notes from the field: Trends in gabapentin detection and involvement in drug overdose deaths\u201423 states and the District of Columbia, 2019\u20132020","volume":"71","author":"Mattson","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chen, C., Winterstein, A.G., Lo-Ciganic, W.H., Tighe, P.J., and Wei, Y.J. (2022). Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with chronic noncancer pain: A population-based cohort study. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1003921"},{"key":"ref_14","unstructured":"US Food and Drug Administration (FDA) (2025, May 28). FDA Warns About Serious Breathing Problems with Seizure and Nerve Pain Medicines Gabapentin (Neurontin, Gralise, Horizant) and Pregabalin (Lyrica, Lyrica CR): When Used with CNS Depressants or in Patients with Lung Problems; FDA Drug Safety Communication. 19 December 2019, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e259043","DOI":"10.1001\/jamanetworkopen.2025.9043","article-title":"The 2016 CDC Opioid Guideline and analgesic prescribing patterns in older adults with cancer","volume":"8","author":"Rodin","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.2019.1347","article-title":"Association of tramadol with all-cause mortality among patients with osteoarthritis","volume":"321","author":"Zeng","year":"2019","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/jamainternmed.2014.6512","article-title":"Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain","volume":"175","author":"Fournier","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1915638","DOI":"10.1001\/jamanetworkopen.2019.15638","article-title":"Association of disability with mortality from opioid overdose among US Medicare adults","volume":"2","author":"Kuo","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/00185787231206522","article-title":"Association of gabapentinoids with opioid-related overdose in the inpatient setting: A single center retrospective case-control study","volume":"59","author":"Humpert","year":"2024","journal-title":"Hosp. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2240612","DOI":"10.1001\/jamanetworkopen.2022.40612","article-title":"Trends in the use of opioids vs nonpharmacologic treatments in adults with pain, 2011-2019","volume":"5","author":"Pritchard","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Fleet, J.L., Dixon, S.N., Kuwornu, P.J., Dev, V.K., Montero-Odasso, M., Burneo, J., and Garg, A.X. (2018). Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193134"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.ajkd.2021.11.007","article-title":"Higher-dose gabapentinoids and the risk of adverse events in older adults with CKD: A population-based cohort study","volume":"80","author":"Muanda","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Prior, A., Vestergaard, C.H., Vedsted, P., Smith, S.M., Virgilsen, L.F., Rasmussen, L.A., and Fenger-Gr\u00f8n, M. (2023). Healthcare fragmentation, multimorbidity, potentially inappropriate medication, and mortality: A Danish nationwide cohort study. BMC Med., 21.","DOI":"10.1186\/s12916-023-03021-3"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s11606-019-04859-1","article-title":"Patients\u2019 and providers\u2019 views on causes and consequences of healthcare fragmentation in the ambulatory setting: A qualitative study","volume":"34","author":"Kern","year":"2019","journal-title":"J. Gen. Intern. Med."},{"key":"ref_25","unstructured":"Centers for Disease Control and Prevention (CDC) (2025, May 28). Prescription Drug Monitoring Programs (PDMPs): What Clinicians Need to Know. 6 May 2024, Available online: https:\/\/www.cdc.gov\/overdose-prevention\/hcp\/clinical-guidance\/prescription-drug-monitoring-programs.html#:~:text=Check%20the%20PDMP:,frequently%20when%20continuing%20opioid%20therapy."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e209085","DOI":"10.1001\/jamanetworkopen.2020.9085","article-title":"Evaluation of Prescription Drug Monitoring Program integration with hospital electronic health records by US county-Level opioid prescribing rates","volume":"3","author":"Holmgren","year":"2020","journal-title":"JAMA Netw. Open"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/3\/345\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:18:29Z","timestamp":1782537509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/3\/345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["medsci14030345"],"URL":"https:\/\/doi.org\/10.3390\/medsci14030345","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]}}}